P423 Long term outcome for sequential rescue treatments in steroid refractory ulcerative colitis – a real life experience

2014 ◽  
Vol 8 ◽  
pp. S242 ◽  
Author(s):  
M. Protic ◽  
F. Seibold ◽  
A. Shoepfer ◽  
Z. Radojicic ◽  
P. Juillerat ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Life Experience ◽  
Real Life ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Steroid Refractory

Long-term outcome of peanut oral immunotherapy-Real-life experience

2018 ◽  
Vol 29 (5) ◽  
pp. 519-526 ◽  
Author(s):  
Liat Nachshon ◽  
Michael R. Goldberg ◽  
Yitzhak Katz ◽  
Michael B. Levy ◽  
Arnon Elizur
Keyword(s):  
Life Experience ◽  
Real Life ◽  
Oral Immunotherapy ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Daniela Pugliese ◽  
Annalisa Aratari ◽  
Stefano Festa ◽  
Pietro Manuel Ferraro ◽  
Rita Monterubbianesi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Maintenance Therapy ◽  
Clinical Remission ◽  
Real Life ◽  
Mucosal Healing ◽  
Cumulative Probability ◽  
Term Outcome ◽  
Long Term Outcome

Background and Aims. Thiopurines are commonly used for treating ulcerative colitis (UC), despite the fact that controlled evidence supporting their efficacy is limited. The aim of this study was to evaluate the long-term outcome of thiopurines as maintenance therapy in a large cohort of UC patients. Methods. All UC patients receiving thiopurine monotherapy at three tertiary IBD centers from 1995 to 2015 were identified. The primary endpoint was steroid-free clinical remission. Secondary endpoints were mucosal healing (MH), defined as Mayo endoscopic subscore 0, long-term safety, and predictors of sustained clinical remission. Results. We identified 192 patients, contributing a total of 747 person-years of follow-up (median follow-up 36 months, range 1–210 months). Steroid dependency was the most common indication for thiopurine treatment (58%). Steroid-free remission occurred in 45.3% of patients; 36.3% stopped thiopurines because of treatment failure and 18.2% for adverse events or intolerance. The cumulative probability of maintaining steroid-free remission while on thiopurine treatment was 87%, 76%, 67.6%, and 53.4% at 12, 24, 36, and 60 months, respectively. MH occurred in 57.9% of patients after a median of 18 months (range 5–96). No independent predictors of sustained clinical remission could be identified. Conclusions. Thiopurines represent an effective and safe long-term maintenance therapy for UC patients.

scholarly journals Long‐term outcome of cyclosporin rescue therapy in acute, steroid‐refractory severe ulcerative colitis

2014 ◽  
Vol 2 (2) ◽  
pp. 108-112 ◽  
Author(s):  
Tamás Molnár ◽  
Klaudia Farkas ◽  
Zoltán Szepes ◽  
Ferenc Nagy ◽  
Mónika Szűcs ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Rescue Therapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Severe Ulcerative Colitis ◽  
Steroid Refractory

Long-term outcome of treatment with cyclosporine IV for patients with intractable ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A624-A624 ◽  
Author(s):  
J ARTS ◽  
M ZEEGERS ◽  
G DHAENS ◽  
G VANASSCHE ◽  
M HIELE ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Term Outcome ◽  
Long Term Outcome

Prevalence and Long-Term Outcome of Sub-Clinical Primary Sclerosing Cholangitis in Patients with Ulcerative Colitis

2020 ◽  
Author(s):  
Emma Culver ◽  
Helen K. Bungay ◽  
Margaret Betts ◽  
Colm Forde ◽  
Otto Buchel ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Sclerosing Cholangitis ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab

2016 ◽  
Vol 10 (9) ◽  
pp. 1015-1023 ◽  
Author(s):  
Konstantinos Papamichael ◽  
Oliviane Rivals-Lerebours ◽  
Thomas Billiet ◽  
Niels Vande Casteele ◽  
Ann Gils ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Term Outcome ◽  
Long Term Outcome

W1807 Long-Term Outcome of Chronic Hepatitis B Patients Initially Treated with Entecavir in a Real-Life Clinical Setting

2009 ◽  
Vol 136 (5) ◽  
pp. A-866
Author(s):  
Nghiem B. Ha ◽  
Nghi B. Ha ◽  
Ruel T. Garcia ◽  
Huy N. Trinh ◽  
Andrew A. Vu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Clinical Setting ◽  
Real Life ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S383-S384
Author(s):  
E Dubois ◽  
A Moens ◽  
J Sabino ◽  
M Ferrante ◽  
S Vermeire
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Remission ◽  
Therapeutic Outcome ◽  
Inactive Disease ◽  
Referral Centre ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Ulcerative Proctitis

Abstract Background Data about long-term prognostic and therapeutic outcome of patients with ulcerative proctitis (UP) are scarce. Real-world data are very important as these patients are usually excluded from participation in randomised controlled clinical trials. Methods All patients diagnosed with ulcerative colitis limited to the rectum (further defined as UP) and followed at our referral centre between 1998 and 2018, were identified via an automated search of electronic medical records and were reviewed for long-term therapeutic outcome. Treatment success was defined as clinical remission (complete disappearance of UP-related symptoms as judged by the treating physician) and endoscopic inactive disease (Mayo endoscopic sub-score of 0 or 1 on sigmoidoscopy) if available at last follow-up. Results From a total of 1561 patients with ulcerative colitis (UC), 168 patients with UP were identified (54% female, mean age at diagnosis 36 years). While the majority (118 patients or 70%) had proctitis since diagnosis, another 50/168 (30%) were diagnosed with left-sided colitis or extensive colitis but had a predominant disease course of proctitis afterwards. Nearly, all patients received treatment with 5-ASA but 71 patients (42%) were refractory to rectal ± oral therapy with 5-ASA and corticosteroids necessitating azathioprine in 41 patients (24%) and/or biological therapies in 59 patients (35%). Azathioprine was started as monotherapy in 34 patients. Anti-TNF was the first-line biological in 45 and vedolizumab in 14 patients. After a median follow-up of 76.5 months (IQR 34.3–143.8), clinical remission was observed in 143 patients (85%) and in 52/71 patients with 5-ASA refractory proctitis (73%). In this last group, clinical remission rates were significantly higher for patients treated with biologicals (44/59 or 75%) as compared with patients treated with azathioprine (8/34 or 24%; p < 0.0001). Conclusion Ten per cent of patients with ulcerative colitis from our referral centre cohort had disease confined to the rectum. With a median follow-up of more than 6 years, good clinical outcomes were recorded with 85% of patients achieving clinical remission. Nevertheless, more than one third needed escalation to biologicals to control the proctitis. Long-term outcome in patients on biologicals was superior to azathioprine. Our data do not suggest inferior outcomes for patients with proctitis compared with left-sided or extensive colitis.

Sign in / Sign up

Export Citation Format

Share Document